janus kinase (JAK) inhibitor - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 all comers	COVID-19 mild to moderate

	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate
janus kinase (JAK) inhibitor
baricitinib	ACTT-2 ... COV-BARRIER	RECOVERY
tofacitinib	STOP-COVID ...		Murugesan

0 studies excluded by filtering options 1